UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 766.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 234,537 shares of the company’s stock after buying an additional 207,456 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.24% of ARS Pharmaceuticals worth $3,401,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. First Turn Management LLC acquired a new position in shares of ARS Pharmaceuticals in the 3rd quarter valued at about $8,603,000. Raymond James & Associates acquired a new position in ARS Pharmaceuticals during the third quarter valued at approximately $2,969,000. Allspring Global Investments Holdings LLC purchased a new stake in ARS Pharmaceuticals during the third quarter worth approximately $2,584,000. Renaissance Technologies LLC grew its stake in ARS Pharmaceuticals by 884.9% during the second quarter. Renaissance Technologies LLC now owns 124,100 shares of the company’s stock worth $1,056,000 after buying an additional 111,500 shares during the period. Finally, SG Americas Securities LLC grew its stake in ARS Pharmaceuticals by 861.5% during the second quarter. SG Americas Securities LLC now owns 111,592 shares of the company’s stock worth $950,000 after buying an additional 99,986 shares during the period. 68.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the company. William Blair upgraded ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Leerink Partners raised their target price on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, September 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $24.00.

ARS Pharmaceuticals Stock Performance

NASDAQ SPRY opened at $11.90 on Friday. ARS Pharmaceuticals, Inc. has a 1 year low of $5.02 and a 1 year high of $18.51. The business’s fifty day moving average is $14.62 and its two-hundred day moving average is $12.34. The stock has a market capitalization of $1.16 billion, a P/E ratio of -23.33 and a beta of 0.88.

Insider Activity at ARS Pharmaceuticals

In related news, CEO Richard E. Lowenthal sold 100,000 shares of ARS Pharmaceuticals stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $12.93, for a total value of $1,293,000.00. Following the transaction, the chief executive officer now owns 1,398,499 shares in the company, valued at $18,082,592.07. This trade represents a 6.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Justin Chakma sold 27,272 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $12.06, for a total value of $328,900.32. Following the sale, the insider now owns 136,380 shares of the company’s stock, valued at approximately $1,644,742.80. The trade was a 16.66 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,268,058 shares of company stock valued at $19,635,686. Company insiders own 40.10% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.